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Background—Restenosis after conventional stenting is almost exclusively caused by neointimal hyperplasia. b-Particle–
emitting radioactive stents decrease in-stent neointimal hyperplasia at 6-month follow-up. The purpose of this study was
to evaluate the 1-year outcome of 32P radioactive stents with an initial activity of 6 to 12 mCi using serial quantitative
coronary angiography and volumetric ECG-gated 3D intravascular ultrasound (IVUS).
Methods and Results—Of 40 patients undergoing initial stent implantation, 26 were event-free after the 6-month follow-up
period and 22 underwent repeat catheterization and IVUS at 1 year; they comprised half of the study population.
Significant luminal deterioration was observed within the stents between 6 months and 1 year, as evidenced by a
decrease in the angiographic minimum lumen diameter (20.4360.56 mm; P50.028) and in the mean lumen diameter
in the stent (20.5560.63 mm; P50.001); a significant increase in in-stent neointimal hyperplasia by IVUS
(18.16612.59 mm3 at 6 months to 27.75611.99 mm3 at 1 year; P50.001) was also observed. Target vessel
revascularization was performed in 5 patients (23%). No patient experienced late occlusion, myocardial infarction, or
death. By 1 year, 21 of the initial 40 patients (65%) remained event-free.
Conclusions—Neointimal proliferation is delayed rather than prevented by radioactive stent implantation. Clinical
outcome 1 year after the implantation of stents with an initial activity of 6 to 12 mCi is not favorable when compared
with conventional stenting. (Circulation. 2001;103:14-17.)
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Implantation of 32P radioactive stents with activities rangingfrom 3.0 to 12 mCi in coronary artery lesions has been
reported to inhibit neointimal hyperplasia within the stent at
6-month follow-up.1,2 The major limitation of this therapy is
significant renarrowing at the stent edges, which is called the
“candy wrapper” or “edge effect.”1 Catheter-based radiation
significantly reduces the recurrence of restenosis 6 months
after percutaneous transluminal coronary angioplasty for
in-stent restenosis, but 3-year follow-up reveals greater lumi-
nal deterioration in g-radiation–treated patients.3,4 Such find-
ings indicate the need for longer follow-up beyond the
traditional 6 months in patients treated with intracoronary
radiation. The purpose of this study was to assess late results
after the implantation of radioactive stents using repeat
catheterization with quantitative coronary angiography and
3D intravascular ultrasound (IVUS) at 1 year.
Methods
Patient Population
The European 32P Dose-Response Trial was a nonrandomized mul-
ticenter trial evaluating the safety and efficacy of implanting radio-
active stents with activity levels of 3 to 12 mCi in single, native
coronary artery lesions. All stents were implanted in de novo lesions,
except for 1 case of in-stent restenosis. For the purposes of this
analysis, this case was excluded. Other inclusion and exclusion
criteria, as well as immediate and 6-month results, were previously
reported.1,2 Only patients undergoing 6-month angiographic and
IVUS follow-up who did not experience major adverse cardiac
events during the first 6 months were included. The study was
performed in accordance with the Declaration of Helsinki and the
European Guidelines for Good Clinical Practice. Ethical approval
was provided by the Medical Ethical Committee of the University
Hospital Rotterdam. All patients gave written, informed consent.
Radioactive Stent
The BX Isostent (32P) (Isostent Inc), which is 15 mm in length and
3.0 or 3.5 mm in diameter, was used. The initial activity of the stents
was measured and, thereafter, the date at which the radioactivity
would have decreased to 6 to 12 mCi was calculated.
Procedure and Clinical Follow-Up
Procedural details have been published previously.5 All patients
received either 250 mg of ticlopidine BID or 75 mg of clopidogrel
per day for 3 months after stent implantation and 80 mg of aspirin per
day indefinitely. Revascularization was performed on the basis of
clinical symptoms and/or evidence of ischemia on exercise testing.
Clinical end points were death, Q-wave myocardial infarction,
non–Q-wave myocardial infarction (creatine kinase-MB rise .2
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times normal upper limit), target vessel revascularization, non–target
vessel revascularization, and early and late thrombotic occlusion of
the target vessel.
Angiographic and IVUS Procedures
Angiography in multiple projections was performed before the
procedure, after stenting, and at 6-month and 1-year follow-up. The
stented vessel segments were examined with quantitative coronary
angiography (CAAS II analysis system,6,7 Pie Medical BV) and
mechanical IVUS (CardioVascular Imaging System). IVUS images
were acquired to coincide with the peak of the R wave by using an
ECG-triggered pullback device with a stepping motor at 0.2 mm/
step. This system eliminates the artifacts caused by the movement of
the heart during the cardiac cycle.8 The ECG-gated image acquisition
and digitization was performed by a workstation designed for 3D
reconstruction (EchoScan, Tomtec). A Microsoft Windows-based
contour detection program was used for the volumetric 3D analysis.8
Core Laboratory Analysis Procedures
Quantitative coronary angiography using at least 2 orthogonal
projections was performed. For analytical purposes, the following 3
regions of interest were defined: (1) stent, (2) target lesion, and
(3) target vessel. The stent included only the radioactive stent. The
target lesion was defined as the stent and 5 mm proximal and 5 mm
distal to the edge. The target vessel was defined as the target lesion
and the remaining segments of the treated vessel. Target lesion
restenosis was defined as .50% diameter stenosis, located within
the target lesion, at follow-up.9 Edge restenosis was defined as
.50% diameter stenosis, located at the proximal and/or distal edge,
at follow-up.
Quantitative IVUS analysis of the stent and 5 mm proximal and
distal to the stent was performed. Lumen and stent boundaries were
detected using a minimum cost algorithm. Total stent and lumen
volumes were calculated as previously described.8 Neointimal vol-
ume was calculated as stent volume minus luminal volume. Feasi-
bility, reproducibility, and interobserver and intraobserver variability
of this system have been validated in vitro and in vivo.8
Statistical Analysis
Data are presented as mean6SD. Continuous data were compared
using repeated measures ANOVA or a 2-tailed Student’s t test as
appropriate.
Results
Baseline demographics and lesion characteristics are shown
in Table 1. Between 6 months and 1 year, target lesion
revascularization and target vessel revascularization were
performed in 4 patients (18%) and 5 patients (23%), respec-
tively. No late occlusion was seen. No patient died or
experienced myocardial infarction. In total, 21 of 40 patients
(53%) were event-free through the 1-year follow-up.
Quantitative Coronary Angiography and
IVUS Measurements
Quantitative coronary angiography data, presented as a sub-
segmental analysis of the stent area and the edges, are shown
in Table 2. A significant decrease in the minimum and mean
lumen diameters was noted between 6 months and 1 year
(P50.028 and P50.001, respectively) compared with both
edges. The late loss of mean lumen diameter was significantly
larger after 6 months than before 6 months. Furthermore, in
11 patients (50%), the minimum lumen diameter at the edge
at 6 months was detected within the stent at 1 year (“migra-
tion” from the stent edge to within the stent). Lesion progres-
TABLE 1. Baseline Characteristics of the 22 Patients Studied
Male sex 20 (91)
Age, y 57 (38–73)
Risk factors
Previous MI 12 (55)
Diabetes mellitus 3 (14)
Hyperlipidemia 18 (82)
Hypertension 9 (41)
Smoking 8 (36)
Family history 7 (32)
CCS class 3/4 15 (68)
Treated vessel
LAD 12 (55)
LCx 5 (22.5)
RCA 5 (22.5)
Lesion type
A 2 (9)
B1 10 (45.5)
B2 8 (36.5)
C 2 (9)
Lesion length, mm 1063
Values are n (%), mean (range), or mean6SD. MI indicates myocardial
infarction; CCS, Canadian Cardiovascular Society; LAD, left anterior descending
coronary artery; LCx, left circumflex artery; and RCA, right coronary artery.
TABLE 2. Subsegmental Quantitative Coronary Angiography Analysis
Baseline 6 Months 1 Year
Late Loss
Baseline to 6
Months
6 Months to
1 Year Total
P Between
Periods
Minimum lumen diameter, mm
Proximal edge 2.9260.53 2.2360.73* 2.0860.50 0.6960.80† 0.1560.51‡ 0.84 0.060
Stent 2.5060.47 2.3660.47* 1.9360.52* 0.1460.52† 0.4360.56‡ 0.57 0.16
Distal edge 2.2960.61 2.1760.58 2.0860.49 0.3660.49† 0.0960.49‡ 0.45 0.9
Mean lumen diameter, mm
Proximal edge 3.1960.56 2.7360.57* 2.5060.40* 0.3960.62§ 0.2260.51\ 0.61 0.33
Stent 3.1260.42 3.0960.58 2.5460.41* 0.0360.62§ 0.5560.63\ 0.68 0.041
Distal edge 2.6460.56 2.5160.56 2.3660.50 0.1260.49§ 0.1660.52\ 0.28 0.9
*P,0.05, †P50.0041, ‡P50.025, §P50.028, \P50.001 by ANOVA.
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sion to .50% diameter stenosis was observed in 5 patients.
This was due to a progression of in-stent restenosis in 4
patients and a progression of a proximal stent-edge lesion in
the other.
IVUS was completed in 19 patients; omissions were due to
equipment failure2 or patient clinical instability.1 IVUS anal-
ysis demonstrated a significant increase in neointimal hyper-
plasia between 6 months and 1 year (18.16612.59 mm3 to
27.75611.99 mm3; increase of 52.8%; P50.001), mainly in
the mid and distal portions of the stent (Figure 1). An increase
in neointimal hyperplasia .25% (range, 25% to 360%)
occurred in 12 cases (63%), as shown in Figure 2. No change
in lumen volume was noted at the stent edges between 6
months and 1 year.
Radiation Doses
The radioactive stents had a mean activity of 8.661.6 mCi at
implantation and delivered 58610 Gy to a depth of 1 mm
from the stent at 100 days, with a dose rate of .15cGy/h.
There was no correlation between stent activity or delivered
dose and changes in minimum or mean lumen diameter at
6-month or 1-year follow-up.
Discussion
A worrying late progression of in-stent neointimal hyperpla-
sia was observed between 6 months and 1 year after the
implantation of radioactive stents, leading to target vessel or
lesion reintervention in 5 of 26 patients (19%) who had been
event-free at 6 months. The event-free rate at 1 year after the
implantation of 6 to 12 mCi radioactive stents was 21 of 40
patients (53%), which compares poorly to the expected
outcome after the implantation of a nonradioactive stent.10
In contrast to the tissue growth seen in malignancy, the
DNA synthesis that occurs after nonradioactive stenting in
experimental models terminates after 6 weeks.11 At this time
point, the activity of the radioactive stent used in this study
would have been sufficient to inhibit cellular proliferation.
Thereafter, the majority of lumen deterioration occurs in the
first 3 months after conventional stent implantation, with
minimal change between 6 months and 1 year,12–14 and actual
regression of neointimal hyperplasia between 1 and 3 years
after stenting.15 This latter phenomenon has been attributed to
a reduction in the proteoglycan content of hyperplastic
tissue.16 Accordingly, the findings reported here of “break-
through” or “rebound” hyperplasia causing further lumen
deterioration between 6 months and 1 year must be inter-
preted as being specific to the effects of radioactivity,
presumably due to a fall- off in radiation levels. The obser-
vation that the radioactive stent may provide a substrate for
atherosclerosis may well have been predicted by Carter et al’s
porcine model.17
Because no significant stenosis progression was observed
at the stent edges among our patients, the candy wrapper
effect may be considered a short-term healing response to
vessel wall injury beyond the stented vessel segment com-
bined with the effects of low-dose radiation.18,19
Unexpected late luminal deterioration has also been re-
ported between 6 months and 3 years among patients treated
by catheter-based g-radiation after repeat intervention for
in-stent restenosis (mean loss of 0.37 mm with 4 of 17
patients [26%] progressing to restenosis [diameter stenosis
.50%]), compared with no major changes in the placebo
group.4 The difference in the time frame of this virtual
“rebound hyperplasia” between radioactive stenting and
catheter-based g-radiation therapy may be a function of the
biological effects of and response to the type and dosage of
radiation administered. Alternatively, late loss may also have
Figure 1. Mean neointimal area in stent at 6 months (n) and 1
year () using IVUS.
Figure 2. Cumulative distribution curve of
percent changes in late neointimal growth
after 6 months, as measured by IVUS.
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occurred between 6 months and 1 year and remained subclin-
ical in the catheter-based study.
Conclusions
Neointimal hyperplasia is delayed rather than prevented by
radioactive stent implantation. The combination of this phe-
nomenon of rebound hyperplasia with the established phe-
nomenon of edge restenosis calls into question the clinical
applicability of radioactive stenting using current approaches.
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